Summit Securities Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Summit Securities Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-439	Closed	-$3.29K	–	1096
2025 Q1	$3.29K	Buy	+439	New	+$3.54K	﹤0.01%	637
2024 Q4	–	Sell	-412	Closed	-$3K	–	642
2024 Q3	$3K	Buy	+412	New	+$3.13K	﹤0.01%	447
2019 Q2	–	Sell	-16,255	Closed	-$132K	–	325
2019 Q1	$132K	Buy	+16,255	New	+$139K	0.02%	188

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summit Securities Group's BCRX Position: Q2 2025 in Review

Summit Securities Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 439 shares — an estimated $3.29K sold.

Summit Securities Group first reported a position in BCRX in Q1 2019 and held it in 3 quarters. The position peaked at $132K in Q1 2019. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Summit Securities Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Summit Securities Group sold 439 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $3.29K.
Summit Securities Group first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 3 quarters.
Summit Securities Group's BioCryst Pharmaceuticals position peaked at $132K in Q1 2019.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.